Valuation: Amarin Corporation plc

Market Cap 252M 227M 209M 190M 355M 23.98B 359M 2.51B 996M 12.57B 948M 927M 39.85B P/E 2026 *
-171x
P/E 2027 * -199x
Enterprise Value 90.14M 80.9M 74.7M 67.74M 127M 8.56B 128M 896M 356M 4.49B 338M 331M 14.23B EV / Sales 2026 *
0.51x
EV / Sales 2027 * 0.44x
Free-Float
86.93%
Yield 2026 *
-
Yield 2027 * -
1 day+5.94%
1 week+10.77%
Current month-1.92%
1 month-3.77%
3 months-8.60%
6 months-8.67%
Current year-8.63%
1 week 11.25
Extreme 11.25
12.77
1 month 11.25
Extreme 11.25
13.28
Current year 11.25
Extreme 11.25
17.31
1 year 11.25
Extreme 11.25
18.5
3 years 7.08
Extreme 7.08
27.4
5 years 7.08
Extreme 7.08
97.8
10 years 7.08
Extreme 7.08
522.4
Manager TitleAgeSince
Chief Executive Officer 63 04/06/2024
Director of Finance/CFO 42 23/10/2024
Compliance Officer 56 15/11/2023
Director TitleAgeSince
Director/Board Member 63 04/06/2024
Director/Board Member 43 28/02/2023
Director/Board Member 67 28/02/2023
Date Insider Type Main position Quantity % Market Cap. Importance
8/1/26 A Exercice

Chief Financial Officer

781 0.0002%
7/1/26 A Exercice

Chief Operating Officer

9,302 0.0022%
7/1/26 A Exercice

Chief Technology Officer

9,263 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
+6.19%+10.77%-32.68%-6.95% 252M
-3.10%-4.19%+32.67%+59.47% 63.48B
+2.71%+2.29%+12.94%+83.95% 54.55B
-0.85%+1.41%+10.91%+103.02% 53.59B
+2.94%+0.84%+27.89%+57.46% 44.75B
+2.24%-3.35%+17.89%+100.16% 41.62B
+0.49%-4.28%+219.68%+913.41% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+23.47%+37.63%+93.09%+81.12% 26.7B
+3.72%-6.23%+26.01%-8.28% 23.36B
Average +3.64%-0.66%+41.94%+142.80% 38.07B
Weighted average by Cap. +2.22%-1.27%+46.15%+158.90%

Financials

2026 *2027 *
Net sales 177M 159M 147M 133M 249M 16.85B 252M 1.76B 700M 8.83B 666M 652M 28.02B 177M 159M 147M 133M 248M 16.8B 251M 1.76B 698M 8.8B 664M 650M 27.92B
Net income -26.62M -23.89M -22.06M -20.01M -37.39M -2.53B -37.85M -265M -105M -1.33B -99.94M -97.8M -4.2B -18.32M -16.44M -15.18M -13.77M -25.73M -1.74B -26.05M -182M -72.29M -912M -68.76M -67.29M -2.89B
Net Debt -162M -146M -134M -122M -228M -15.41B -231M -1.61B -640M -8.08B -609M -596M -25.62B -175M -157M -145M -131M -246M -16.61B -249M -1.74B -690M -8.71B -656M -642M -27.61B
Projected Income Statement - Annual - Amarin Corporation plc
Logo Amarin Corporation plc
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Employees
80
Date Price Change Volume
28/10/26 $12.63 +5.67% 50,376
27/10/26 $11.95 -1.16% 56,894
26/10/26 $12.09 +2.54% 64,818
23/10/26 $11.79 +1.64% 83,274
22/10/26 $11.60 +0.78% 27,363
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Amarin Corporation plc
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
2
Last Close Price
11.95USD
Average target price
12.50USD
Spread / Average Target
+4.60%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amarin Corporation plc
  1. Stock Market
  2. Stocks
  3. AMRN Stock